|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Lindner, L. H.
(2019):
Multimodale Therapien bei Sarkomen: Standards und Neues in der medikamentösen und radioonkologischen Behandlung.
In: Chirurg, Bd. 90, Nr. 6: S. 457-461
Schoffski, P.; Wozniak, A.; Kasper, B.; Aamdal, S.; Leahy, M. G.; Rutkowski, P.; Bauer, S.; Gelderblom, H.; Italiano, A.; Lindner, L. H.; Hennig, I.; Strauss, S.; Zakotnik, B.; Anthoney, A.; Albiges, L.; Blay, J. -Y.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. A. van der; Debiec-Rychter, M.; Sciot, R.; Cann, T. van; Marreaud, S.; Raveloarivahy, T.; Collette, S. und Stacchiotti, S.
(2018):
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 29, Nr. 3: S. 758-765
Schoffski, P.; Wozniak, A.; Stacchiotti, S.; Rutkowski, P.; Blay, J.-Y.; Lindner, L. H.; Strauss, S. J.; Anthoney, A.; Duffaud, F.; Richter, S.; Grünwald, V.; Leahy, M. G.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. van der; Sciot, R.; Debiec-Rychter, M.; Cann, T. van; Marreaud, S.; Lia, M.; Raveloarivahy, T.; Collette, L. und Bauer, S.
(2017):
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 28, Nr. 12: S. 3000-3008
Lindner, L. H.
(2017):
Translationale Highlights 2016/17 incl. phase-I-data.
In: Oncology Research and Treatment, Bd. 40: S. 16
Harnicek, D.; Kampmann, E.; Lauber, K.; Hennel, R.; Cardoso Martins, A. S.; Guo, Y.; Belka, Claus; Mörtl, S.; Gallmeier, E.; Kanaar, R.; Mansmann, Ulrich; Hucl, T.; Lindner, L. H.; Hiddemann, Wolfgang und Issels, R. D.
(2016):
Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
In: International Journal of Cancer, Bd. 139, Nr. 2: S. 467-479
Ray-Coquard, I.; Rizzo, E.; Blay, J. Y.; Casali, P.; Judson, I.; Krarup Hansen, A.; Lindner, L. H.; Dei Tos, A. P.; Gelderblom, H.; Marreaud, S.; Litiere, S.; Rutkowski, P.; Hohenberger, P.; Gronchi, A. und Graaf, W. T. van der
(2016):
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
In: Gynecologic Oncology, Bd. 142, Nr. 1: S. 95-101
Issels, R. D.; Lindner, L. H.; Verweij, J.; Wust, P.; Reichardt, P.; Schem, B. C.; Abdel-Rahman, S.; Daugaard, S.; Salat, C.; Wendtner, C. M.; Vujaskovic, Z.; Wessalowski, R.; Jauch, K. W.; Durr, H. R.; Ploner, F.; Baur-Melnyk, Andrea; Mansmann, Ulrich; Hiddemann, Wolfgang; Blay, J. Y. und Hohenberger, P.
(2010):
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
In: Lancet Oncology, Bd. 11, Nr. 6: S. 561-570